Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000520422 | SCV000620124 | pathogenic | not provided | 2022-10-31 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Athena Diagnostics | RCV000520422 | SCV001880729 | likely pathogenic | not provided | 2021-01-06 | criteria provided, single submitter | clinical testing | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). |
Labcorp Genetics |
RCV003581683 | SCV004273563 | pathogenic | Charcot-Marie-Tooth disease type 4 | 2024-09-26 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly631Glufs*5) in the FGD4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FGD4 are known to be pathogenic (PMID: 17564972). This variant is present in population databases (rs751035912, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with FGD4-related conditions. ClinVar contains an entry for this variant (Variation ID: 451425). For these reasons, this variant has been classified as Pathogenic. |